Literature DB >> 32426915

Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis.

Kohei Otsubo1,2, Eiji Iwama1, Kayo Ijichi3, Naoki Kubo1, Yasuto Yoneshima1, Hiroyuki Inoue1, Kentaro Tanaka1, Atsushi Osoegawa4, Tetsuzo Tagawa4, Yoichi Nakanishi1, Isamu Okamoto1.   

Abstract

The pathogenesis of lung cancer associated with idiopathic pulmonary fibrosis (IPF) has remained largely uncharacterized. To provide insight into this condition, we undertook genomic profiling of IPF-associated lung cancer as well as of adjacent fibrosing lung tissue in surgical specimens. Isolated DNA and RNA from 17 IPF-associated non-small cell lung cancer and 15 paired fibrosing lung tissue specimens were analyzed by next-generation sequencing with a panel that targets 161 cancer-related genes. Somatic genetic alterations were frequently identified in TP53 (n = 6, 35.3%) and PIK3CA (n = 5, 29.4%) genes in tumor samples as well as in EGFR (n = 7, 46.7%), PIK3CA (n = 5, 33.3%), ERBB3 (n = 4, 26.7%), and KDR (n = 4, 26.7%) in IPF samples. Genes related to the RAS-RAF signaling pathway were also frequently altered in tumor (n = 7, 41.2%) and IPF (n = 3, 20.0%) samples. The number of somatic alterations identified in IPF samples was almost as large as that detected in paired tumor samples (81 vs 90, respectively). However, only 6 of the 81 somatic alterations detected in IPF samples overlapped with those in paired tumor samples. The accumulation of somatic mutations was thus apparent in IPF tissue of patients with IPF-associated lung cancer, and the RAS-RAF pathway was implicated in lung tumorigenesis. The finding that somatic alterations were not frequently shared between tumor and corresponding IPF tissue indicates that IPF-associated lung cancer does not develop through the stepwise accumulation of somatic alterations in IPF.
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  cancer-related gene; idiopathic pulmonary fibrosis; lung cancer; next-generation sequencing; somatic alteration

Year:  2020        PMID: 32426915     DOI: 10.1111/cas.14488

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

Review 1.  The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.

Authors:  Giulia Maria Stella; Vito D'Agnano; Davide Piloni; Laura Saracino; Sara Lettieri; Francesca Mariani; Andrea Lancia; Chandra Bortolotto; Pietro Rinaldi; Francesco Falanga; Cristiano Primiceri; Angelo Guido Corsico; Andrea Bianco
Journal:  Transl Lung Cancer Res       Date:  2022-03

2.  Genomic analysis between idiopathic pulmonary fibrosis and associated lung cancer using laser-assisted microdissection: A case report.

Authors:  Yuko Iida; Yasuhiro Gon; Yoko Nakanishi; Yusuke Kurosawa; Yoshiko Nakagawa; Kenji Mizumura; Tetsuo Shimizu; Noriaki Takahashi; Shinobu Masuda
Journal:  Thorac Cancer       Date:  2021-03-30       Impact factor: 3.500

3.  Idiopathic Pulmonary Fibrosis Complicated by Adenocarcinoma and Organizing Pneumonia.

Authors:  Yu Inutsuka; Toyoshi Yanagihara; Kotaro Matsumoto; Reiko Yoneda; Mikiko Hashisako; Naruhiko Ogo; Tatsuma Asoh; Takashige Maeyama
Journal:  Cureus       Date:  2022-01-04

4.  Diagnostic Value of Serum Levels of IL-22, IL-23, and IL-17 for Idiopathic Pulmonary Fibrosis Associated with Lung Cancer.

Authors:  Qian Zhang; Lihong Tong; Bing Wang; Ting Wang; Hongxia Ma
Journal:  Ther Clin Risk Manag       Date:  2022-04-19       Impact factor: 2.755

5.  Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis.

Authors:  Yasuto Yoneshima; Eiji Iwama; Shingo Matsumoto; Taichi Matsubara; Testuzo Tagawa; Keiichi Ota; Kentaro Tanaka; Mitsuhiro Takenoyama; Tatsuro Okamoto; Koichi Goto; Masaki Mori; Isamu Okamoto
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.